197 related articles for article (PubMed ID: 9740973)
21. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
22. Prostatic specific antigen for prostate cancer detection.
Nogueira L; Corradi R; Eastham JA
Int Braz J Urol; 2009; 35(5):521-9; discussion 530-2. PubMed ID: 19860930
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
[TBL] [Abstract][Full Text] [Related]
24. Evidence of prostate cancer screening in a UK region.
Gavin A; McCarron P; Middleton RJ; Savage G; Catney D; O'Reilly D; Keane PF; Murray LJ
BJU Int; 2004 Apr; 93(6):730-4. PubMed ID: 15049981
[TBL] [Abstract][Full Text] [Related]
25. Baseline PSA in a Spanish male population aged 40-49 years anticipates detection of prostate cancer.
Angulo JC; Viñas MA; Gimbernat H; Fata FR; Granados R; Luján M
Actas Urol Esp; 2015 Dec; 39(10):605-11. PubMed ID: 26099906
[TBL] [Abstract][Full Text] [Related]
26. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
Bangma CH; Kranse R; Blijenberg BG; Schröder FH
Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
28. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
[TBL] [Abstract][Full Text] [Related]
30. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening.
Finne P; Finne R; Bangma C; Hugosson J; Hakama M; Auvinen A; Stenman UH
Int J Cancer; 2004 Aug; 111(2):310-5. PubMed ID: 15197788
[TBL] [Abstract][Full Text] [Related]
31. Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia.
Dantanarayana ND; Hossack T; Cozzi P; Brooks A; Lau H; Delprado W; Patel MI
BMC Urol; 2015 Dec; 15():124. PubMed ID: 26715039
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
33. PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study.
Karlsen RV; Larsen SB; Christensen J; Brasso K; Friis S; Tjønneland A; Dalton SO
Acta Oncol; 2013 Nov; 52(8):1609-14. PubMed ID: 23978293
[TBL] [Abstract][Full Text] [Related]
34. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
el-Galley RE; Petros JA; Sanders WH; Keane TE; Galloway NT; Cooner WH; Graham SD
Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
[TBL] [Abstract][Full Text] [Related]
35. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
[TBL] [Abstract][Full Text] [Related]
36. Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012.
Wallner LP; Hsu JW; Loo RK; Palmer-Toy DE; Schottinger JE; Jacobsen SJ
Urology; 2015 Sep; 86(3):498-505. PubMed ID: 26123517
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
38. [Screening for early detection of prostate cancer (first experience in Israel)].
Neheman A; Shotland Y; Metz Y; Stein A
Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
[TBL] [Abstract][Full Text] [Related]
39. Screening for prostate cancer in New Zealand general practice.
Zuzana O; Ross L; Fraser H; Charis B; Alistair S; Leanne T; Michael H; Peter G
J Med Screen; 2013 Mar; 20(1):49-51. PubMed ID: 23612467
[TBL] [Abstract][Full Text] [Related]
40. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]